Lv6
2770 积分 2023-01-12 加入
Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors
2天前
已完结
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
8天前
已完结
Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors
9天前
已完结
Promising Response to Lurbinectedin in NUT Carcinoma: a case report and review of emerging therapeutic strategies
11天前
已完结
Constitutional mosaicism of pathogenic variants in SMARCB1 in a subset of patients with sporadic rhabdoid tumors
11天前
已关闭
cIMPACT-NOW Update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas
11天前
已完结
Use of Erdafitinib in FGFR3-Mutated Recurrent Respiratory Papillomatosis
16天前
已关闭
Use of Erdafitinib in FGFR3-Mutated Recurrent Respiratory Papillomatosis
17天前
已关闭
Antibody-drug conjugates for targeted cancer therapy: recent advances in potential payloads
22天前
已完结
Optimizing the safety of antibody–drug conjugates for patients with solid tumours
22天前
已完结
Gastrointestinal Stromal Tumors With KIT Exon 9 Mutations
皖公网安备34019202002308
